Press Release: European Medicines Agency starts review of orlistat-containing medicines

Author (Corporate)
Series Title
Series Details EMA/CHMP/771335/2011 (22.9.11)
Publication Date 22/09/2011
Content Type

The European Medicines Agency (EMA), in September 2011, started a review of orlistat-containing anti-obesity medicines, to determine whether the very rare cases of hepatic injury have an impact on their benefit-risk profile and conditions of use. The review includes the centrally authorised prescription-only medicine Xenical (orlistat 120 mg) and the centrally authorised over-the-counter-medicine Alli (orlistat 60 mg), as well as a number of medicines containing orlistat that have either already or are in the process of being authorised at national level.
Source Link http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/09/news_detail_001345.jsp&mid=WC0b01ac058004d5c1&murl=menus/news_and_events/news_and_events.jsp
Related Links
EMA: Press Release: EMA/CHMP/771335/2011 (22.9.11) http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/09/WC500112798.pdf
Subject Categories
Countries / Regions